Clinical Read2026-06-01

Individualized neoantigen therapy intismeran autogene (intismeran) plus pembrolizumab - (KEYNOTE-942)

Moderna Inc.MRNA
Indication
Resected melanoma
Stage
phase2
Event
Phase 2b